FDA Ignores OTC Firms’ Expertise On Drug Naming In Draft Guidance
This article was originally published in The Tan Sheet
Executive Summary
CHPA says FDA’s draft guidance on developing proprietary drug names ignores that OTC manufacturers assess risks for all aspects of their products, including names, prior to launch.